Predicting response to immunosuppressive therapy and survival in severe aplastic anaemia.
about
How I treat acquired aplastic anemiaEltrombopag in aplastic anemiaImmunosuppressive therapy for transplant-ineligible aplastic anemia patients.Paroxysmal nocturnal hemoglobinuria clones in severe aplastic anemia patients treated with horse anti-thymocyte globulin plus cyclosporine.Peripheral blood lymphocyte telomere length as a predictor of response to immunosuppressive therapy in childhood aplastic anemia.Multiparameter flow cytometry for the diagnosis and monitoring of small GPI-deficient cellular populationsShort telomeres result in chromosomal instability in hematopoietic cells and precede malignant evolution in human aplastic anemia.Impact of age on outcomes after bone marrow transplantation for acquired aplastic anemia using HLA-matched sibling donorsEltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug.Recent advances in treatment of aplastic anemia.Increased bone marrow (BM) plasma level of soluble CD30 and correlations with BM plasma level of interferon (IFN)-γ, CD4/CD8 T-cell ratio and disease severity in aplastic anemiaEltrombopag Added to Standard Immunosuppression for Aplastic Anemia.Optimization of therapy for severe aplastic anemia based on clinical, biologic, and treatment response parameters: conclusions of an international working group on severe aplastic anemia convened by the Blood and Marrow Transplant Clinical Trials NePredicting response to immunosuppressive therapy in childhood aplastic anemia.Decreased infection-related mortality and improved survival in severe aplastic anemia in the past two decades.Efficacy of rabbit anti-thymocyte globulin in severe aplastic anemia.A novel marker for screening paroxysmal nocturnal hemoglobinuria using routine complete blood count and cell population data.Should we still use Camitta's criteria for severe aplastic anemia?Eltrombopag and improved hematopoiesis in refractory aplastic anemia.Paroxysmal nocturnal hemoglobinuria and telomere length predicts response to immunosuppressive therapy in pediatric aplastic anemia.Aplastic anemia: pathophysiology and treatment.Anemia of Central Origin.Success of allogeneic marrow transplantation for children with severe aplastic anaemia.Association of telomere length of peripheral blood leukocytes with hematopoietic relapse, malignant transformation, and survival in severe aplastic anemia.The Third Consensus Conference on the treatment of aplastic anemia.Treatment of refractory or relapsed acquired aplastic anemia: review of established and experimental approaches.Antibodies in the treatment of aplastic anemia.Diagnosis of acquired aplastic anemia.Alternative immunosuppression in patients failing immunosuppression with ATG who are not transplant candidates: Campath (Alemtuzumab).The optimal immunosuppressive therapy for aplastic anemia.Prognostic value of telomere attrition in patients with aplastic anemia.Clinical Outcomes in Adult Patients with Aplastic Anemia- a single institution experience.Current management of severe acquired aplastic anemia.Post-therapeutic recovery of serum interleukin-35 level might predict positive response to immunosuppressive therapy in pediatric aplastic anemia.Clinical significance of acquired somatic mutations in aplastic anaemia.Biomarkers for predicting clinical response to immunosuppressive therapy in aplastic anemia.Evaluation of efficacy of alemtuzumab in 5 patients with aplastic anemia and/or myelodysplastic neoplasmPredictors of early mortality after rabbit antithymocyte globulin as first-line treatment in severe aplastic anemia.Meta-analysis of treatment with rabbit and horse antithymocyte globulin for aplastic anemia.Deep phenotyping of Tregs identifies an immune signature for idiopathic aplastic anemia and predicts response to treatment
P2860
Q24617687-EC50C708-E715-42A6-9135-1A2B904BBA60Q28085299-DF637F94-F4A2-4532-8519-60704D40008CQ33419679-3E7FED0C-8D21-4B81-B6FE-2C9A2904D532Q33952747-1F62BD9A-C9C1-4115-8D13-605EC22F9010Q33978891-8BA216F9-5954-470D-9949-3061CC93F113Q34118127-5527EEF4-DC4C-4C9F-8F8B-A8AAAFFAB868Q34212939-30B44A5C-8459-42CA-B86F-34530A56ABDEQ34371142-5181C2AF-CDF6-4E0E-B540-CFABE6DAFFC5Q34392449-D2F22BFD-2EA1-47E4-A83A-25DCC2675C07Q34451351-174F472E-AA19-4CDD-9002-79AF0CB522EEQ34482699-0367C8C2-21D2-4925-AB14-A7F790C60DFCQ34555435-ECC3A693-4C68-4AC1-843A-603B054F43A5Q34645147-88B31558-05E5-4B9F-BFA7-06A2F4F94E5EQ34890595-7921D449-1342-4B23-AB44-CB5406886E52Q35019920-2BA7488A-7087-43E9-8AE9-D97D83BE3FDFQ35193715-418BDF86-2473-4D28-89CD-90573A540CE7Q35536766-6B103126-14A8-4048-8E5E-8FD3E5C6BE5AQ36074027-0D59EC7C-1344-4E4F-BD78-2EBAB37F662AQ36174878-403888DE-496A-487B-8B95-AE2157D9EEC8Q36337581-5C53920D-F985-45EB-BC5E-E787B57FF178Q36464602-019118DB-C806-4B87-B213-30712E5853C6Q36784115-595A5E18-0C74-49F6-BA1C-3C9CBDEE438CQ36958013-FBB947AD-D235-49F1-8D1E-38D336A606D1Q37040876-362BDAB0-FF13-495E-A126-103A9675270AQ37880645-84117D4A-0905-444F-9C85-703C57D9F329Q37884078-C5A3ADD8-E177-47F9-AB8D-377C1F6A28CCQ37981576-386A9419-552A-465E-B81E-BCFA2484114DQ38061043-72237A9A-5359-4B78-B2A2-62692127B5A2Q38065877-2D47E996-2F53-4E09-B445-5F5152B9ACF3Q38100685-E9FD7EB0-C78A-4005-9D65-DAD6A5A77AD9Q38103469-367919C9-7084-4A56-8C34-493CC28FFF62Q38636146-3D79A3D7-3F9E-4CCF-9015-7467A1269096Q38694686-7B0C40C2-02DE-4E49-AC04-0B5E1B94F9F5Q38756198-7671488C-BA45-4B50-A97E-C93D9249261CQ38809618-810425C5-0BAB-4B75-9709-709B45F1EE51Q38811464-41B70E64-5EAC-4AA4-9187-8DBED9CF8DEFQ39289359-5B81178C-A79C-4317-876F-CBCD4EE55D67Q40090645-E068B80E-D41C-41E8-BD80-5CE0FE056F7DQ40384599-8CA5F1E3-B2C7-4F2F-9869-86FF8B5D4150Q41004126-329CCE17-EC5B-4318-9967-953842F27524
P2860
Predicting response to immunosuppressive therapy and survival in severe aplastic anaemia.
description
2008 nî lūn-bûn
@nan
2008 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Predicting response to immunosuppressive therapy and survival in severe aplastic anaemia.
@ast
Predicting response to immunosuppressive therapy and survival in severe aplastic anaemia.
@en
Predicting response to immunosuppressive therapy and survival in severe aplastic anaemia.
@nl
type
label
Predicting response to immunosuppressive therapy and survival in severe aplastic anaemia.
@ast
Predicting response to immunosuppressive therapy and survival in severe aplastic anaemia.
@en
Predicting response to immunosuppressive therapy and survival in severe aplastic anaemia.
@nl
prefLabel
Predicting response to immunosuppressive therapy and survival in severe aplastic anaemia.
@ast
Predicting response to immunosuppressive therapy and survival in severe aplastic anaemia.
@en
Predicting response to immunosuppressive therapy and survival in severe aplastic anaemia.
@nl
P2093
P2860
P1476
Predicting response to immunosuppressive therapy and survival in severe aplastic anaemia.
@en
P2093
Colin O Wu
Neal S Young
Olga Nunez
Phillip Scheinberg
P2860
P304
P356
10.1111/J.1365-2141.2008.07450.X
P407
P577
2008-11-19T00:00:00Z